"The integration of GeneCards(R) will be the first step of our cooperation with Xennex", said Dr. Thure Etzold, CEO of LION bioscience. "The GeneCards(R) database is very well known and provides rich and very useful information about genes and gene products. It is a logical extension to our products."
Dr. David Warshawsky, CEO of Xennex added: "We are extremely pleased about our relationship with LION. Both SRS and GeneCards(R) are widely used and recognized tools. We believe that providing SRS customers with the ability to integrate GeneCards(R) with LION's proven technology will enable SRS users worldwide to benefit fully from GeneCards(R) and will enhance the value of the SRS platform."
SRS is a proven, scalable and robust data integration platform that provides fast access to diverse life sciences data - genetic, protein, cellular, molecular and clinical -- from public and proprietary sources, regardless of data format. SRS is used in more than 300 commercial and academic sites delivering genomic data daily to thousands of users around the globe. SRS is the market leader for bioinformatics data integration, providing global bioinformatics platforms for pharmaceutical companies such as Eli Lilly, Johnson&Johnson and AstraZeneca, as well as the preferred search engine for genomics portals from leading data providers such as Celera, Incyte and Derwent.
GeneCards(R) is a digital compendium of human genes and their encoded proteins, with major focus on functional genomics and medical aspects, including involvement in diseases. GeneCards(R) offers concise information about the structure and function of human genes. It extracts, integrates and compares a carefully selected subset of gene information, obtained from major data sources, public and proprietary, successfully overcoming barriers of data format heterogeneity. GeneCards(R) is unique in its combination of user-friendly interface, as well as the organization and display of just the right mix of links and detailed information. Data are divided into "fields" such as "Aliases", "Location", "Ontologies", "Expression" and "SNPs", all searchable by keywords. Since GeneCards(R) employs automatic data mining from dozens of sources; it provides a truly complete summary for each gene. GeneCards(R) (http://genecards.weizmann.ac.il) was developed over the last 8 years by a world-leading bioinformatics team at the Weizmann Institute of Science in Israel.
For further information please contact:
LION bioscience Tracy Coffey Director Global Communications +1 857 919 9975 email@example.com
Xennex Inc. Dr. David Warshawsky, Ph.D., Chief Executive Officer +1 617 497 7774 firstname.lastname@example.org
Xennex, Inc. (www.xennexinc.com) is a dynamic privately held company that is dedicated to providing Biotechnology, Pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property, the highest level of services and tools to enhance their gene-based research. Xennex' products help such organizations to optimize their efforts to develop innovative medical products and services. Xennex operations worldwide are carried out from its offices in Massachusetts, USA.
Xennex' customers include many of the world leading biotech and pharmaceutical companies, located in North America, Europe and Japan. Xennex' products are used in hundreds of commercial and academic organizations by thousands of users around the globe.
About LION bioscience
LION bioscience (ISIN: DE0005043509, Reuters: LIOG, Bloomberg: LIO) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. Since it was founded in 1997, the company has become a recognized leader in the area of bioinformatics. LION has operations worldwide in Heidelberg, Germany, Cambridge, UK and Cambridge, MA, USA. LION's products are distributed by CTC Laboratory Systems in Japan and DigiGenomics in Taiwan. LION's (http://www.lionbioscience.com) solutions are used by more than 27,000 researchers at 300 academic and industrial customers globally.
Except for the historical information contained herein, the matters set forth in this press release are forward looking within the meaning of the Private Securities Litigation Reform Act of 1995, and other applicable U.S. and German laws. These forward-looking statements may include projections, assumptions, estimates, targets, and descriptions of future events. Such statements are based on currently available information and on LION's current expectations as to future events that may not prove to be accurate. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Many factors could cause the actual results, performance or achievements of LION to be materially different from those that may be projected, expected, targeted, expressed or implied by such statements. All roll-out plans and future dates with respect to completion of development and market release of LION products are target dates only based on the company's current planning and may change in the future. Any delays in the current product release schedule will have a materially adverse effect on the company's targets for fiscal year. We refer you to LION's Annual Reports on Form 20-F, as recently filed with the Securities and Exchange Commission (SEC) on September 30, 2004 (Form 20-F), in which these and other risk factors are discussed. In the event of any material conflicts between the two documents, Form 20-F should be relied on. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained in this announcement, whether as a result of new information, change of assumptions or business model, future developments or otherwise.